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Prom1/CD133 has been identified in colorectal, hepatocellular, and pancreatic cancer as a
cancer stem cell marker and has been used as such to predict colon cancer recurrence in
humans. Its potential molecular function as well as its role as a marker of intestinal regen-
eration is still not fully known. We evaluated the role of Prom1 in intestinal regeneration in
inflammatory bowel disease (IBD), determined the function of Prom1, and characterized
the effect of a lack of Prom1 on intestinal tumor formation in animal models. Our results
suggest that Apc mutations lead to an increase in Prom1 expressing cells in the intestinal
crypt stem cell compartment and in early intestinal adenomas. Also, Prom1 knockout mice
are more susceptible to intestinal tumor formation. We conclude that Prom1 likely plays
a role in regulating intestinal homeostasis and that these results clearly illustrate the role
of Prom1 in intestinal regeneration. We further conclude that Prom1 may provide a novel
therapeutic target for patients with gastrointestinal conditions such as IBD, short bowel
syndrome, and colorectal cancer.
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INTRODUCTION
The intestinal tract is lined by mucosa, which is primarily com-
posed of villi or the intercrypt table and epithelial-lined crypts at
the mucosal base (1–4). The mucosal epithelial cells arise from
intestinal stem cells located in the crypt (5). The morphological
and functional characterization of intestinal stem cells could shed
light on their role in intestinal regeneration. The Clever laboratory
found that PROM1 is a marker for stem cells and early progeni-
tors in the mouse small intestine and that it meets all the criteria
of putative intestinal stem cells (6). However, its role as a marker
of intestinal regeneration is largely unknown.
PROM1 is a cell surface membrane protein and is a homolog
to the CD133 protein in human (7). PROM1 was identified as
both a hematopoietic and neuroepithelial stem cell marker (8–
11). The function of Prom1 is unknown, but its specific local-
ization suggests that PROM1 is involved in the organization of
plasma membrane protrusions, and suggests that PROM1 might
be important in maintaining an appropriate lipid composition
within the plasma membrane (12). In addition, PROM1 has been
identified in the apical plasma membrane of epithelial cells of pan-
creas (13), liver (canals of Hering, interlobular ducts) (14), kidney
(15), prostate (16), and skin (17). In the small intestine in mouse,
Prom1 marks rare stem cells, as well as transit-amplifying prog-
enitor cells (6). Moreover, PROM1 is expressed in both rod and
cone photoreceptors of the eye (18, 19). Prom1 also has been used
as a cancer stem cell marker alone or with other markers such
as CD44 (20). Singh and Dirks found that PROM1 expressing
neural tumor cells are essential for tumorigenesis (21). Tang et al.
found that PROM1 positive cell populations are more tumorigenic
than PROM1 negative cells in the liver (22). In colon cancer, both
PROM1 positive and PROM1 negative cells are capable of being
tumorigenic (23). However, PROM1 expression in colon cancer
in humans was found to be predictive of increased colon cancer
recurrence (24, 25).
Wnt signaling regenerative pathways control intestinal differen-
tiation (26, 27). Upon Wnt pathway activation,β-catenin stabilizes
and translocates to the nucleus where it accumulates. It then, in
cooperation with the transcription factor Tcf-4, modulates expres-
sion of a variety of Tcf-4 responsive target genes such as Paneth
cell alpha defensins (28–30). However, whether Prom1 expres-
sion is downstream of the Wnt and β-catenin/TCF transactivation
activity is not clear.
Inflammation in the colon can play a significant role in
colon cancer development (31). For example, the significantly
increased risk of developing colon cancer in patients with long-
standing inflammatory bowel disease (IBD) has been thought
in large part to result from chronic colonic inflammation (31).
The physiologic role of Prom1 in intestinal inflammation related
to colon cancer development is not known. Characterization
of Prom1 holds significant promise for eventual treatment of
intestinal tumors and many gastrointestinal diseases such as
Crohn’s Disease. We hypothesize that the Wnt signaling regen-
erative pathway results in dysregulation of Prom1 expression
and subsequent changes in intestinal mucosal repair, and hence
may be relevant to colon cancer development in IBD. To test
this hypothesis, we investigated the role of Prom1 in intestinal
regeneration and tumorigenesis. To gain insights into Prom1, we
generated Prom1 knockout mice. Prom1 knockout mice were
more susceptible to azoxymethane (AOM)/dextran sodium sul-
fate (DSS) induced intestinal inflammation, which promoted
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colorectal tumorigenesis. Also, loss of Prom1 gene contributed
to higher tumorigenicity in Apc mutant mice.
MATERIALS AND METHODS
ANIMAL TREATMENTS
Wild type (Wt ), Prom1 knockout mice (Prom1-/-), and Apc mutant
mice (Apc-/+) ranging from 1 day to 5 months old were used. Wt
and 129-Apctm1.∆716 mice were bred in our animal facility (27).
Prom1-/- mice were provided by Dr. Kyuson Yun (un-published).
To generate double mutant Apc-/+Prom1-/- mice, 129-Apc-/+ were
crossed with 129-Prom1−/− mice. All animals were maintained
on a 129SvEv background (>10 generations). Pups were geno-
typed by PCR to determine Apc and Prom1 gene status. The
wild-type Prom1 allele generated a 204-bp product,and the mutant
allele formed a 329-bp product. Mice were fed an AIN-76A diet
and water ad libitum, exposed to 12-h-light/12-h-dark cycles, and
maintained under specific pathogen free conditions without pin-
worms, Helicobacter spp, or Citrobacter rodentium. We used age-
and sex-matched littermate controls. All animal experiments were
performed in accordance with protocols approved by the Ani-
mal Care and Use Committee of the Johns Hopkins Medical
Institutions.
ANALYSIS OF INTESTINAL ADENOMA
At the age of 4 months, Apc-/+Prom1-/- and Apc-/+Prom1+/+
female mice were euthanized by cervical dislocation. The intestines
were opened, stained with methylene blue (Figure 7A), and the
number of adenomas was counted as previously described (27).
ABERRANT CRYPT FOCI
Aberrant crypt foci (ACF) were induced using AOM and DSS.
Six-week-old female Wt and Prom1-/- mice (N = 5 per group) fed
an AIN-76A diet and water ad libitum were treated with a single
dose of AOM (2.5, 5, 7.5, or 10 mg/kg in saline, i.p.). Mice were
assessed every 12 h for 5 days. Another group of Wt and Prom1-/-
mice (N = 10 per group) were treated with a single dose of AOM
(5 mg/kg in saline, i.p.). Seven days after injection with AOM,
the mice were given normal drinking water or drinking water
containing 2% DSS for a period of 7 days followed by normal
drinking water for 3 weeks. ACF in surviving mice were evaluated
as previously described with minor modifications (32). Intesti-
nal lesions were scored for the presence of inflammation, mucosal
damage, and proliferation. Grade 0, normal intestine; Grade 1,
mild mixed infiltration of inflammatory cells; Grade 2, moder-
ate infiltration of mixed inflammatory cells and edema within the
mucosal layer and mild epithelial crowding; Grade 3, moderate to
severe inflammation, edema, mucosal disruption, and crypt pro-
liferation (epithelial crowding, deep crypts, and thicken mucosa);
and Grade 4, severe transmural inflammation, edema, mucosal
disruption, and severe proliferation (thickened mucosa, elongated
and branched crypts, loss of goblet cells).
SERUM CHEMISTRY AND BLOOD EXAMINATION
At the age of 6 weeks, blood was taken from both Wt and Prom1-/-
mice. Both serum and blood were sent to Antech Diagnostics
for analysis. Serum was analyzed for liver, kidney, and pancreas
functions as well as muscle changes. The blood exam included
total red blood cells (RBC), total white blood cells (WBC), and dif-
ferential WBC counts. Thrombin, partial thrombin, hemoglobin,
packed cell volume, mean corpuscular hemoglobulin (MCH), and
mean corpuscular hemoglobulin concentration (MCHC) were
also measured.
IMMUNOFLUORESCENCE AND IMMUNOHISTOCHEMICAL STAINING
The adult Wt, Prom1−/−, and Apc-/+ mice were euthanized
by cervical dislocation. The intestines were opened longitu-
dinally, washed in PBS, and fixed in 10% buffered formalin.
Then, the intestines were rolled and submitted for embedding.
Five-micrometer-thick sections were prepared, and sections were
deparaffinized in xylene and rehydrated through graded alcohols.
Slides were transferred to a jar containing unmasking solution
(Vector Laboratories, H-3300), boiled for 10 min, and left in the
same solution at room temperature for 20 min. All slides were
then incubated with 10% blocking serum (Vector Laboratories),
in PBS for 30 min at room temperature. The slides were incu-
bated with primary antibody (anti-Prom1, MAB4310, or with
anti-Ki67, AB9260, Millipore) diluted 1:100 for 60 min at room
temperature. After three washes with 0.1% Tween 20 in PBS,
sections were incubated for 30 min with fluorescence (for Prom1)
or non-fluorescence (for Ki67) biotinylated secondary antibody
IgG (Vector laboratories) diluted 1:500 in blocking solution. Slides
were washed three times in PBS for 3 min each, and rinsed three
times with distilled water. Cover slips were mounted with crys-
tal mount (Biomeda, M02). The number of positive cells within
the crypts and adenomas was quantified in 10 fields at 400×
magnification for Prom1 and at 200× magnification for Ki67.
Photographs of histological sections were taken using a Nikon
digital camera.
WESTERN BLOT ANALYSIS
Western blot analyses were performed on SDS-PAGE gels under
denaturing conditions. Total proteins (30µg/ml) from both Wt
and Prom1-/- mice from intestinal crypt preparations were sepa-
rated on 12 or 15% gels and electrotransferred onto nitrocellulose
membranes (BioRad,162-0115). Non-specific protein binding was
blocked using 10% Blotto–0.1% Tween followed by incubation
with anti-Prom1 primary antibody (Millipore, MAB4310) diluted
in the blocking solution overnight at 4°C. After washing with
PBS, membranes were incubated with horseradish peroxidase-
conjugated anti-mouse secondary antibodies and developed using
the Immobilon Western Kit (Millipore, WBKLS0100).
REAL-TIME PCR
Real-time PCR was performed to determine Prom1 expression on
the crypt cells from both Wt and Prom1-/-. Total RNA of mouse
intestinal tissues were extracted using the RNAeasy Kit (Invitro-
gen), and cDNA was synthesized using random hexamers. The
Taqman primers for the Prom1 and K19 genes were from Applied
Biosystems. We calculated relative gene expression by the ∆CT
method.
DATA ANALYSIS
Data are presented as the mean and SEM or as a percentage
with SD (GraphPad, PRISM software, San Diego, CA, USA). The
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Mann–Whitney test was used to compare body weights, and P
values were determined using the Student two-tailed t -test unless
otherwise indicated. Tumor data were analyzed using the Chi
square (χ2) test and other differences using the Student’s t -test.
Kaplan–Meier survival curves were generated, and difference in
survival was determined using the log-rank test. Data were con-
sidered to be significantly relevant at p< 0.05 and are presented
as mean± SEM.
RESULTS
IDENTIFICATION AND CHARACTERIZATION OF Prom1 IN NORMAL
INTESTINAL CRYPT STEM CELL COMPARTMENTS AND IN EARLY
PREMALIGNANT LESIONS IN MICE
Immunofluorescence staining for the normal epithelial cell crypts
in both the small and the large intestines revealed that anti-
PROM1 antibody marked rare intestinal crypt cells (Figure 1A).
In the Apc-/+ mice, that anti-PROM1 antibody showed intense
staining in the majority of the epithelial cells within the adeno-
mas (Figures 1B,C). The isotype matched control was negative
(data not shown). Quantification showed an expansion of PROM1
positive cells in the adenomas, P < 0.001 (Figure 1D). Western
blot analysis showed that mucosal cells from Apc-/+ mice have
an enhanced expression of PROM1 in comparison to normal
crypts from wild-type mice (Figure 2A). Real-time PCR was per-
formed on the crypt cells using K19 or Gadph (data not shown
for Gadph) as controls. Results demonstrated significant increases
(four- to six-fold) in Prom1 expression in the crypt epithelial cells
in the Apc-/+ mice compared to the crypts from wild-type mice
(Figure 2B). These results indicate that Prom1 expression and
PROM1 positive cells are increased in the mucosa of Apc-/+ mice.
ROLE OF Prom1 DURING NORMAL GROWTH AND DEVELOPMENT IN A
KNOCKOUT ANIMAL MODEL SYSTEM
To determine the role of Prom1 in intestinal crypt, we ana-
lyzed Prom1-/- mice. Null mice of both sexes were phenotypi-
cally normal, and crossing heterozygous male and female mice
resulted in Wt, Het, and null offspring at the expected Mendelian
ratios (Figure 3). Body weight analysis revealed mature obesity
in Prom1-/- mice compared to Wt mice (Figure 4A). Complete
histopathological analysis revealed that there is a moderate degree
of germinal arrest in the testes of Prom1-/- mice compared to wild-
type mice. There was multifocal seminiferous tubule atrophy and
degeneration and arrest of spermatogenesis within the testes in
the Prom1-/- mice at 4 months of age (Figure 4C). Serum chem-
istry revealed a significant increase in fasting blood glucose level
in Prom1-/- mice. The mean blood glucose level was 254 mg/dl in
the Prom1-/- mice compared to 158 mg/dl in the wild-type mice
(Figure 4B). The knockout did not affect hematology. There were
no changes in blood scores in the Prom1-/- mice compared to
wild-type mice (data not shown).
INFLUENCE OF Prom1-/- GENOTYPE ON INTESTINAL MUCOSAL
HEALING AND PROLIFERATION DURING INTESTINAL INJURY IN MICE
To determine whether Prom1 has a role in maintaining intestinal
epithelium homeostasis and injury response, we exposed con-
trol and Prom1-/- to AOM and DSS. Prom1-/- mice were more
FIGURE 1 | Immunofluorescence staining using PROM1 in antibodies for
the detection of expanded positive cells from crypt cells in Wt mice and
within the adenomas in Apc−/+ mice. (A) Normal crypt (magnification,
×600). (B) Adenoma (magnification, ×100). (C) Higher magnification (×600)
of the image (B). (D) Quantification analysis of the positive cells within the
crypt and adenomas in the Apc−/+ mice. Bar=SEM. *p<0.01 (n=10).
FIGURE 2 | Affect of Apc−/+ on Prom1 expression. (A) Protein expression of PROM1 from small and large intestine inWt mice and Apc−/+ mutant mice from
three different mice. (B) mRNA expression of Prom1 from large intestine ofWt and Apc−/+ mice (n=4).
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sensitive to AOM than Wt mice. After injection with a single dose
of AOM (5 mg/kg), 50% of the mice died. All the Prom1-/- mice
died when given a single injection of AOM at 7.5 or 10 mg/kg
(Figure 5A). Remarkably, an injection of AOM followed by oral
exposure to DSS resulted in increased intestinal inflammation
in Prom1-/- mice, relative to Wt mice (Figures 5C,D). Inflam-
matory infiltrate consists predominantly of macrophages, neu-
trophils, and lesser numbers of lymphocytes and rare plasma cells.
In addition to increase in inflammation, Prom1-/- mice showed
severe dysplastic crypts and abnormal crypt proliferation. Hyper-
plastic crypts in the knockout mice showed markedly reduced
number of goblet cells, elongated nuclei with prominent nucle-
oli, and abnormal crypt lumen. The wild-type mice exhibited
mild crypt hyperplasia with minimal dysplasia. Peripheral com-
plete blood counts revealed significant leukocytosis, neutrophilia,
and monocytosis in Prom1 knockout mice compared with the
wild-type mice (Figure 5B). The proliferation index of hyper-
plastic crypts measured by nuclear expression of Ki67 showed
a significant positive correlation to the lack of Prom1, p< 0.01
(Figure 6).
FIGURE 3 | Genotypes of offspring obtained by cross-mating of
Prom1−/+ and Prom1−/+ double heterozygous mice. (A) PCR of Prom1
heterozygous, wild type, and homozygous genomic DNA to detect mutant
allele. (B) Mendelian ratios, single gene (Prom1) knockout.
EFFECT OF Prom1-/- ON INTESTINAL TUMOR GROWTH
To determine whether loss of Prom1 promotes intestinal tumori-
genesis, we crossed Prom1-/- mice to Apc-/+ mice. All sizes of
adenomas increased in the double mutant mice (Apc-/+Prom1-/-)
(Figure 7A), especially small adenomas (<2 mm in diameter)
(Figure 7B). Double mutant mice exhibited the highest number
of adenomas (mean, 33) compared with Apc−/+ mice (mean, 27)
along their entire small and large intestines at ~120 days of age.
Average adenoma count was 23 in the small intestine and 10 in the
large intestine of double mutant mice (Apc-/+Prom1-/-) compared
to 17 and 10 in single mutant mice (Apc-/+Prom+/+), respectively.
The number of adenomas increased by 18% in Apc-/+Prom1-/-
mice compared to those with Apc-/+Prom+/+. This escalation
was highly significant as mediated by a p value of <0.05 using
a two-tailed Student’s t -test.
DISCUSSION
Despite medical advances, IBD remains a significant and increas-
ing health care burden worldwide, and the exact cause remains
unknown (33). However, intestinal regeneration plays an impor-
tant role in the healing of the intestinal mucosa (34). We hypoth-
esized that PROM1 is important for intestinal homeostasis. The
results reported here demonstrate that Prom1 plays an important
role in intestinal healing. Knockout of Prom1 results in signifi-
cantly greater intestinal inflammation, abnormal crypt prolifera-
tion, and dysplasia upon AOM/DSS administration. Inflammation
in general promotes intestinal tumorigenesis (35). The use of
PROM1 to mark the intestinal stem cells and colorectal cancer
is controversial (36). Researchers found that both PROM1+ cells
and PROM1– cells are capable of tumorigenicity and display simi-
lar differentiation capabilities. For example, Liqin Zhu found that
Prom1 marks stem cells in the adult small intestine that are sus-
ceptible to transformation into tumors (37). In contrast, Meng
FIGURE 4 | Phenotype of Prom1 knockout mice. (A) Body weight change from day 1 to day 94. (B) Blood glucose level at 6 weeks of age inWt and Prom1− /−
mouse (n=10). (C) Histopathological examination of the testes at 4 months of age showing empty seminiferous tubules in the Prom1− /− mouse (arrow),
H&E ×100.
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FIGURE 5 | Significant differences in survival and inflammation in the Wt
and Prom1−/− treated group. (A) Survival curve ofWt and Prom1−/− mice
after AOM administration that was assessed every 12 h for 5 days.
(B) Peripheral leukocyte counts ofWt and Prom1−/− mice after AOM/DSS
administration. (C) H&E of large intestine inWt and Prom1− /− mice after
AOM/DSS administration. Notice: inflammation, dysplastic crypts, and
abnormal proliferation in knockout mice. (D) Scores of inflammation in the
inflamed colon. (*p<0.05 compared with control, n=6 animals/group).
FIGURE 6 | Proliferation assay in Wt and Prom1−/− mice after AOM/DSS administration. Immunohistochemical staining of Ki67 within the crypts inWt
(A) and Prom1− /− (B) mice. (C) Quantification analysis of Ki 67 staining. Bar=SEM. *p<0.01 (n=10).
et al. discovered that PROM1 alone could not be used as a stem
cell marker because PROM1+ cells and PROM1− cells displayed
similar abilities of colony formation, self-renewal, proliferation,
and differentiation (38). Our results show that the loss of Prom1
combined with Apc gene heterozygosity significantly increases
tumorigenesis. Together, these results suggest that Prom1 functions
as a protective factor against early phase, inflammation-mediated
tumorigenesis.
Several investigators found that PROM1 is a target for Wnt
signaling regenerative pathways in many cell lines including malig-
nant melanoma and glioblastoma cells (39, 40). In the absence of
Wnt, Apc forms a complex in the cytoplasm that results in β-
catenin phosphorylation by glycogen synthase kinase-3 (GSK-3).
This results in proteolytic degradation of β-catenin. Loss of
Apc function and GSK-3 phosphorylation results in stabilized
β-catenin (41, 42). This in turn allows β-catenin to translocate
to the nucleus and accumulate, where, in cooperation with the
transcription factor Tcf-4, it modulates expression of a variety
of Tcf-4 responsive target genes such as Paneth cell α-defensins
(28–30). However, it was not clear whether Prom1 behaves as a
positive or negative regulator in mice having Apc mutations. Our
results are consistent with previous studies showing that PROM1 is
expressed predominantly on the crypt stem cell compartment. We
now show that PROM1 can also be detected in early premalignant
lesions in Apc-/+ mice under Wnt signaling regenerative pathways
and that Prom1-/- deletion stimulates adenomas in Apc-/+ mice,
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FIGURE 7 | (A) Methylene blue staining of the entire intestine is shown.
Notice various sized of adenomas within the large (arrow head) and small
intestine (arrows). (B) Distribution of adenomas by size in Apc-/+ prom1+ /+
(white bar) and in Apc-/+ Prom1-/- mice (filled bar). The percentage of control
adenomas is indicated with SEM. The number of adenomas was analyzed
by the Chi-square test and Student’s t -test (*p< 0.05 versus control, n= 15
animals/group).
which is a part of Wnt signaling regenerative pathways. These data
indicate that Prom1-/- is a potential target for chemoprevention
treatment. The anticancer activity of PROM1 is unknown, and
that is beyond the scope of this paper. Taken together, our results
suggest that Prom1-/- induces inflammation and increases prolif-
erative potential in the intestinal crypts enhanced intestinal tumor
genesis.
Knockout of Prom1 did not affect early development in
mice; Prom1-/- disruption did not cause any lethal embryonic
defects or interfere with development or fertility, although we did
observe compromised spermatogenesis in some Prom1−/− males.
Histopathological analysis concluded that Prom1 is essential for
maintenance of healthy testicular tissue. Also, Prom1-/- mice were
significantly obese and had increased in fasting blood glucose as
compared with control to Wt mice. Therefore, there appears to be
a link between Prom1 and pancreatic islet cell function. Epidemio-
logical associations of both diabetes and obesity with colon cancer
risk have been well-established (43). It will be of great interest to
determine if decreased Prom1 presence or activity has a role in
the relationships between diabetes or obesity and risk for colon
cancer in humans. Review manuscript suggests that there is a link
between colon cancer progression and obese individual due to
mitochondrial dysfunction (44, 45).
To our knowledge, this is the first study to provide an in-depth
evaluation of the role and function of Prom1. Given the strong
influence of Prom1 presence and control of progression of inflam-
mation and development of dysplastic crypts, as well as limiting
tumorigenesis in the presence of Apc loss, one may hypothesize
that PROM1 may have a role in inflammation-mediated colonic
dysplasia such as that which occurs not infrequently in long-
standing IBD of the colon in humans. It will be of great interest
to determine if PROM1 presence or activity is reduced in human
IBD and particularly in IBD-associated dysplasia and colon cancer.
Our findings may also imply that accommodation of the Prom1
pathway by small molecules might be a useful chemopreventive
strategy in long-standing IBD. Our results also raise additional
questions to be addressed in future studies regarding Prom1 func-
tion: if overexpression of Prom1 in proliferative intestinal crypts
is mediated by Wnt signaling regenerative pathways and if Prom1
expression acts as a negative regulator in intestinal tumorigenesis,
what role does Prom1 play in Wnt responses? Furthermore, does
expression of Prom1 contribute to the maintenance of “cancer
stemness”?
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